Steadymed Ltd  

(Public, NASDAQ:STDY)   Watch this stock  
Find more results for STDY
-0.11 (-3.52%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.12 - 3.23
52 week 2.85 - 9.70
Open 3.15
Vol / Avg. 1,110.00/11,203.00
Mkt cap 82.74M
P/E     -
Div/yield     -
EPS -1.04
Shares 26.56M
Beta     -
Inst. own 57%
Mar 27, 2018
Q4 2017 Steadymed Ltd Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 2925.47% -2429.01%
Operating margin 2812.73% -2572.58%
EBITD margin - -2514.37%
Return on average assets 81.35% -81.62%
Return on average equity 153.39% -120.72%
Employees 28 -
CDP Score - -


5 Oppenheimer Street
REHOVOT, 7670105
+972-3-6449556 (Phone)
+972-3-6449558 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. Its product candidates are enabled by its PatchPump. Its Trevyent offers a way of administration of treprostinil for subcutaneous or intravenous treatment of PAH patients. The Company's ketorolac At Home Patient Analgesia (AHPA) product candidate is used for the short-term (approximately five days) management of moderately severe acute pain that requires analgesia at the opioid level in a post-surgical setting.

Officers and directors

Keith Bank Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Jonathan M.N Rigby President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
David W. Nassif Chief Financial Officer, Executive Vice President
Age: 63
Bio & Compensation  - Reuters
Elizabeth A. Cermak Independent Director
Age: 59
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Ron Ginor M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Donald D. Huffman Independent Director
Age: 70
Bio & Compensation  - Reuters
Brian Jay Stark Independent Director
Age: 62
Bio & Compensation  - Reuters